We want every man with prostate cancer – or at risk of it - to have access to the same high-quality diagnosis, treatment and care, no matter where in the UK he lives.
The Prostate Cancer UK Best Practice Pathway makes this possible.
We want every man with prostate cancer – or at risk of it - to have access to the same high-quality diagnosis, treatment and care, no matter where in the UK he lives.
The Prostate Cancer UK Best Practice Pathway makes this possible.
Developed to support healthcare professionals at the front line of prostate cancer diagnosis and care, our Best Practice Pathway uses easy to follow flowcharts to guide healthcare professionals deliver best practice diagnosis, treatment and support. It sets out how to achieve an early diagnosis in men at higher than average risk of the disease. It also supports use of the most up-to-date, cutting-edge research-led innovations - so that healthcare professionals are equipped and supported to provide the very latest evidence-based best practice to their patients.
The Diagnostic Pathway has been developed by leading Urology teams at UCLH, the Christie and Royal Marsden Cancer Vanguards brought together by NHS England and supported by Prostate Cancer UK. It uses evidence from the PROMIS trial and recent innovative one-stop shop prostate cancer diagnostic pilots to create a prostate cancer diagnostic pathway that can deliver to the new time to diagnosis standard of 28 days.
Extract from Best Practice Pathway: Treatment, Active Surveillance
Just as every man is an individual, every treatment pathway is individual and needs to be tailored to the needs of the man. Each man must have the opportunity to make an informed choice about their treatment pathway, having been given detailed information about the treatments available for the stage of their disease, the side effects associated with each of these treatments and the outcomes the treatments will provide. For men with low risk cancer, active surveillance must be presented as a treatment option alongside surgery and radiotherapy.
A prostate cancer diagnosis and its treatments can cause men psychological and physical side-effects that require supportive care. The Support Pathway outlines the breadth of potential side-effects that men can experience while providing detailed guidance on the best practice care and support that can enable these men to achieve a better quality of life. It also offers innovative solutions for stratified follow-up and sets out patient behaviour change initiatives that may prevent recurrence or complications resulting from the unmanaged consequences of treatments.
Extract from Best Practice Pathway: Treatment, Active Surveillance
Prostate Cancer UK worked with clinical experts from urology, medical and clinical oncology, and radiology. We also secured expert input from clinical nurse specialists, general practitioners and the National Institute for Clinical Excellence (NICE) to develop the Best Practice Pathway.
Thanks to this collaboration, the Support Pathway is endorsed by NICE and aligned with their guidance.
In addition, the Best Practice Pathway has been peer reviewed by a Clinical Reference Group (CRG) that has included representatives from all the relevant professional bodies and leading prostate cancer clinical researchers.
The CRG will continue to work with us to make sure that the best practice pathway remains up-to-date and robust.